The TGF-beta superfamily consists of secreted proteins involved in development and a range of vital cellular processes, including signaling, differentiation, metabolism, protein synthesis, motility, and invasion in a microenvironment-dependent manner. Ideally, the body is able to maintain homeostasis, a state in which these proteins achieve an equilibrium supportive of these essential processes. However, imbalances leading to increases or reductions in protein levels can contribute to a host of disease states across multiple therapeutic areas.

Since its founding in 2003, Acceleron has combined robust scientific rationale and rigor with sophisticated protein engineering techniques to engage in targeted fashion the 30+ ligands and 12 receptors of the TGF-beta superfamily to develop novel therapeutic candidates in the areas of pulmonary disease and hematology.

Acceleron’s lead asset in pulmonary disease is designed to address the interplay of signaling between pro-proliferative and anti-proliferative proteins of the TGF-beta superfamily to reduce or potentially reverse pathologic remodeling of pulmonary blood vessels. In hematology, Acceleron scientists engineered a fusion protein to disrupt signaling that prevents the development of mature, healthy red blood cells. This first-in-class erythroid maturation agent is now approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders.